Hamlin P, Farber C, Fenske T, et al. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/refractory B cell malignancies. EHA 2017, abstract S773.
MRD-status 1 jaar na stamceltransplantatie geassocieerd met overleving na 6 jaar
jun 2024 | MM, Stamceltransplantatie